Exploratory Discussion Meeting June 11th, 2020
Dan Lewis Foundation

11:00-4:00 EST

A meeting of the Dan Lewis Foundation for Brain Regeneration Research was held via Zoom Conference on Thursday, June 11th, 2020 from 11:00 a.m. to 4:00 p.m. EST. The primary purposes of this meeting were to promote collaboration between leading scientists in the area of cortical regeneration and to begin planning a research agenda to accomplish the mission of the Foundation. That mission—to identify new biomedical approaches that promote neural regeneration, axonal growth, and synaptogenesis to improve the lives of persons with moderate and severe traumatic brain injuries and their families—was affirmed by group consensus.


Invited scientists attending as presenters and/or discussants were David Margulies, M.D. Sudhir Agrawal, Ph.D., Mark Bear, Ph.D., Randall Carpenter, M.D., Adam Cohen, Ph.D., Graham Dempsey, Ph.D.,  Kevin Eggan, Ph.D., David Gerber, Ph.D.,  Alan Kopin, M.D., and Stephen Strittmatter, M.D., Ph.D.  David Margulies ably moderated this meeting, kept the agenda flowing, and allowed ample room for discussion after each of the thought- provoking presentations which are very briefly described below. 


Hal Lewis gave an overview of the causes, the biomechanical and the biochemical effects of brain injury, particularly moderate and severe brain injury. Hal also provided a synopsis of his son Dan’s story (which can also be accessed elsewhere on our site).


Mark Bear spoke about regulation of cortical synaptogenesis particularly in the visual cortex of infra-human study subjects.


Stephen Strittmatter’s presentation explored molecular restraints on axon plasticity and  neural repair;  and explained some of his lab’s findings regarding promotion of axonal growth and sprouting in the spinal cords of infra-human study subjects.


Kevin Eggan gave an overview of progress in induced pluripotent stem cells and the promise of CNS neuronal cultures. He also spoke about the plausibility of creating useful models for the study of TBI and response to potential pharmaceutical treatment of TBI.


Adam Cohen spoke about cutting-edge technologies in the biosciences with particular attention to optogenetic tools that provide new abilities to study cortex and cortical neurons.


Sudhir Agrawal presented an overview of strategies for using anti-sense oligoneucleotide (ASO) therapies targeted to the central nervous system. He also talked about how research labs and biomedical companies can and have worked efficiently together to develop curative pharmaceuticals for many neurological disorders, particularly those for which specific genetic targets can be identified.


Alan Kopin provided a case study that illustrated how genomic analysis can lead to “down regulation” of a specific gene that is implicated in the neurodevelopmental disorder of a 9 year old boy.


Following this set of presentations, group discussion focused on envisioning and planning a research agenda to find therapeutics to improve outcomes for individuals in the chronic phase of post-TBI recovery. It was generally agreed that a plausible research-based path forward could be formulated. This was a very exciting and forward looking meeting—a meeting in which the collaborative and enthusiastic atmosphere lent promise to reaching the Foundations desired outcomes.  We want to express our deep gratitude to each of these renowned and highly respected scientists who contributed to the success of this meeting. A second meeting of the Scientific Advisory Board of the Foundation, with additional invited participants, will be held during late July or the first part of August.


By Dan Lewis Foundation | Spring 2024 11 Apr, 2024
Graham Dempsey, Ph.D., is a founder and Chief Scientific Officer (CSO) at Quiver Bioscience, a Cambridge, Massachusetts-based biotechnology company focused on the development of medicines for disorders of the nervous system. Dr. Dempsey and his team are working to develop treatments for some of the most challenging unsolved medical issues patients and their families face. Using advanced technologies in human stem cell biology, optogenetics, machine learning, and drug screening, progress is being made to develop medicines that will one-day treat conditions that have been largely untreatable. As the lead scientist for Quiver, formerly Q-State Biosciences, Dr. Dempsey enjoys working with world-class teams to invent, develop, and apply cutting-edge technologies to solve the most difficult challenges in biopharma for the betterment of patients. Dr. Dempsey’s inspiration to dedicate his professional life to science and medicine started at the early age of seven with the tragic loss of his father to an aggressive form of cancer, an experience that has deeply motivated him to this day. He completed his undergraduate studies at the University of Pennsylvania and his doctorate at Harvard University. As a graduate student in the biophysics program at Harvard Medical School, he co-developed ‘Stochastic Optical Reconstruction Microscopy’ or STORM , a light microscope with the ability to resolve nanometer (billionth of a meter, e.g. a hair is 100,000 nanometers thick) scale details of biological materials, an achievement that had been thought to be impossible for over a century. STORM has enabled what researchers call ‘super-resolution imaging’ for visualizing the intricate details of life’s most fundamental unit, the cell. Understanding the inner workings of a cell provides a path to a deeper understanding of the ways in which life is constructed and diseases can manifest. The technology was commercialized by Nikon Instruments for researchers worldwide. Dr. Dempsey left academic science to join Q-State Biosciences as the first hired employee with the goal of bringing advanced technologies developed at Harvard to the study of the brain. The brain, arguably the most complex structure in the known universe, works through electrical communication between brain cells or neurons. This communication is disrupted in all brain disorders but has been near impossible to study for the purposes of effectively developing medicines. Dr. Dempsey and his team over the course of ten years built a technology system that creates human brain models from patient stem cells (i.e. a ‘disease-in-a-dish’) and converts electrical activity of those brain cells into light signals that can be detected with ultra-sensitive microscopes. The resulting signals are analyzed using machine learning to find the patterns of how electrical activity is altered in disease, which can be used to find medicines that correct those changes. The team at Quiver is deploying this technology to take on previously untreatable brain conditions, including rare genetic diseases, such as certain seizure and neurodevelopmental disorders, to common conditions, such as chronic pain and Alzheimer’s disease. Dr. Dempsey’s passion outside of science starts with his family, his wife (and high school sweetheart) and three young daughters, be it traveling the globe to experience new cultures (or simply stare at the ocean), cooking elaborate meals on a Saturday evening, night-time reading of novels to his daughters, or attending live music around Boston. As a native of NJ, he celebrates his roots with visits to family near the Jersey Shore and, whenever possible, attendance at Springsteen concerts and Giants games. Dr. Dempsey is an avid student of history’s great entrepreneurs, spending the sparse remaining minutes of the day reading biographies and listening to podcasts, looking to extract every bit of learning towards taking on the challenges of building a great business while staying true to his family, his Quiver teammates, and his professional mission.
By Dan Lewis Foundation | Spring 2024 11 Apr, 2024
Sheryl Suzanne Nibbs, a legal secretary in a top law firm, started the process of becoming a paralegal as she approached her 40th birthday. She was fancy in her appearance, always making sure her hair, nails, and clothing were in order, a well-kept person, an avid traveler, and her mother’s best friend.
Share by: